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MaBACKGROUND Tobacco use is an important preventable cause of peripheral artery disease (PAD) and a major deter-
minant of adverse clinical outcomes.
OBJECTIVES This study hypothesized that tobacco use by PAD patients would be associated with higher health care
utilization and associated costs.
METHODS We conducted a retrospective, cross-sectional study using 2011 claims data from the largest Minnesota
health plan. The total cohort included individuals with 12 months of continuous enrollment and $1 PAD-related claim.
Tobacco cessation pharmacotherapy billing codes were queried in a subgroup with pharmacy beneﬁts. Outcomes were
total costs, annual proportion of members hospitalized, and primary discharge diagnoses.
RESULTS A PAD cohort of 22,203 was identiﬁed, comprising 1,995 (9.0%) tobacco users. A subgroup of 9,027 with
pharmacy beneﬁts included 1,158 (12.8%) tobacco users. The total cohort experienced 22,220 admissions. The pharmacy
beneﬁts subgroup experienced 8,152 admissions. Within 1 year, nearly one-half the PAD tobacco users were hospitalized,
35% higher than nonusers in the total cohort (p < 0.001) and 30% higher in the subgroup (p < 0.001). In both cohorts,
users were more frequently admitted for peripheral or visceral atherosclerosis (p < 0.001), acute myocardial infarction
(p < 0.001), and coronary heart disease (p < 0.05). Observed costs in the total cohort were $64,041 for tobacco users
versus $45,918 for nonusers. Costs for tobacco users also were consistently higher for professional and facility-based
care, persisting after adjustment for age, sex, comorbidities, and insurance type.
CONCLUSIONS Tobacco use in PAD is associated with substantial increases in PAD-related hospitalizations, coronary
heart disease and PAD procedures, and signiﬁcantly greater costs. The results suggest that immediate provision of to-
bacco cessation programs may be especially cost effective. (J Am Coll Cardiol 2015;66:1566–74)
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1567experiencing high rates of depression, social isola-
tion, and chronic pain. Tobacco use is the single
most important etiological factor for the development
of incident PAD (1,2,5–7).SEE PAGE 1575 CHD = coronary heart disease
COPD = chronic obstructive
pulmonary disease
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
PAD = peripheral artery
diseaseIn individuals with PAD, ongoing tobacco use is
also associated with worsened leg ischemic symp-
toms, a higher incidence of critical limb ischemia,
early failure of all revascularization therapies, a
higher risk of amputation, and higher short-term
rates of nonfatal myocardial infarction (MI), stroke,
and death (3,8,9). Furthermore, continuing use of
tobacco is associated with poorer measures of exer-
cise capacity during treadmill testing and earlier
onset of claudication pain during walking (10–12).
Tobacco users with PAD report a lower quality of life
than nonusers with PAD (13).
PAD patients with a history of tobacco use but who
manage to quit have far higher survival rates than
those who continue using tobacco (8,9,14,15).
Consistent provision of contemporary intensive to-
bacco cessation counseling and pharmacotherapies in
individuals with PAD can greatly improve the adju-
dicated quit rate from 6.8% to 21.3% (16).
Among individuals with PAD who use tobacco, the
high rates of short-term adverse cardiovascular
ischemic events (major adverse cardiac events and
major adverse limb events) suggest that the economic
burden of disease among users may be of particular
signiﬁcance. Recent studies have estimated high
overall PAD-attributable costs (17–20), but none have
assessed the direct health economic contribution of
smoking in this population. Estimates of tobacco-
associated medical care utilization and costs within
a PAD population are essential for informing alloca-
tion of scarce resources, targeting efforts toward PAD
prevention, providing tobacco cessation best prac-
tices, offering focus for future PAD clinical care
guidelines, and implementing cost-effective treat-
ments. This study was designed to provide these es-
timates and could inform future practice-based
resource allocation.
METHODS
This study was performed using data derived from
a large national health plan, Blue Cross Blue Shield
of Minnesota (Blue Cross). With a history of more
than 75 years, Blue Cross is the largest and oldest
health plan operating in Minnesota and covers
2.7 million members in the state and nationwide
through its health plans or plans administered by
its afﬁliates. A retrospective, cross-sectional study
design was used.DATA AND STUDY POPULATION. We extrac-
ted insured enrollee 2011 administrative
claims data for individuals at least 40 years of
age who were either commercially insured,
government program enrollees, or enrolled in
a Blue Cross Medicare supplemental plan.
Commercially insured individuals included
members of fully and self-insured health
plans; public program enrollees included
members in the Prepaid Medical Assistance
Program (Minnesota’s Medicaid managed-
care program), as well as MinnesotaCare, a
state-subsidized program for low-income employed
persons. We excluded data from employer groups
who do not allow Blue Cross to use their data for
research purposes (<5%). We restricted our study
population to individuals with 12 months of contin-
uous plan enrollment to assure that clinical event and
cost data collection were maximally complete. The
primary study population focused on all continuous
medical plan enrollees (the total PAD cohort). We also
a priori identiﬁed a subpopulation with both a medi-
cal and pharmacy beneﬁt plan (pharmacy subgroup).
This pharmacy beneﬁt subgroup ostensibly permitted
more speciﬁc identiﬁcation of current tobacco users
via their prescribed tobacco cessation medications
(e.g., varenicline, nicotine replacement therapies,
and buproprion).
As in previous publications (17–20), we used In-
ternational Classiﬁcation of Diseases-Ninth Revision-
Clinical Modiﬁcation (ICD-9-CM) diagnosis and pro-
cedure codes to identify individuals with PAD in
medical claims. The speciﬁc diagnosis and procedure
codes for case ascertainment are shown in Online
Table 1. Diagnosis codes found in the ﬁrst through
ﬁfth positions on medical claims incurred in 2011
were considered positive for PAD. If any of the listed
procedure codes were found in these claims, then the
individual was identiﬁed as having PAD. Those in-
dividuals with lower extremity amputation codes
(ICD-9: 84.xx) found in combination with diagnostic
codes for cancer or trauma on the same service date
(Online Table 2) were excluded, as this combination
of codes is suggestive of a non-PADrelated ampu-
tation. By design, the study population included in-
dividuals with prevalent PAD (of unknown duration)
and not just newly identiﬁed (incident) cases.
Patient descriptive information obtained from 2011
administrative membership ﬁles included age, sex,
and geographic residence (Minnesota and border
counties vs. national). The presence of comorbid
conditions in 2011 (renal failure and cancer) or car-
diovascular ischemic events (MI or stroke), and
known risk factors for PAD (hypertension and
Duval et al. J A C C V O L . 6 6 , N O . 1 4 , 2 0 1 5
Smoking Costs in PAD O C T O B E R 6 , 2 0 1 5 : 1 5 6 6 – 7 4
1568diabetes) were also identiﬁed using ICD-9-CM diag-
nosis codes (Online Table 3).
Online Table 4 lists the administrative billing codes
used to identify tobacco use as the key exposure
variable. For simplicity, we use the terms “tobacco
use” and “smoking” interchangeably. In the total PAD
cohort, smoking was deﬁned in medical claims using
a combination of ICD-9-CM diagnosis codes and Cur-
rent Procedural Terminology (CPT-4) codes (21–23).
As was feasible by review of pharmacy claims, we also
included National Drug Codes to assess smoking
status with increased speciﬁcity in our pharmacy
subgroup. Individuals were considered current or
recent smokers if at least 1 of these codes was iden-
tiﬁed in these claims during the study period of
interest.
OUTCOME MEASURES/ANALYSIS. The economic
analysis was conducted from the health care system
perspective with a primary outcome of annual total
direct medical costs in 2011, including all Blue
Cross expenditures, as well as other insurance and
member payments (patient copayments, deductibles,
and coinsurances). Total costs included facility-based
care (hospital- and skilled nursing facilitybilled
services and procedures) as well as costs for profes-
sional care (primarily, physician-billed services). For
the subset of enrollees with pharmacy beneﬁts, we
included pharmacy expenditures in the primary
outcome of total costs. Other resource utilization
outcomes of interest included the number of hospi-
talizations, the proportion of the population hospi-
talized, and associated primary hospital discharge
diagnoses. All costs presented reﬂect 2011 dollars
and economic results are reported in accordance
with guidelines for health economic evaluations
from the International Society For Pharmacoeco-
nomics and Outcomes Research and its Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) statement (24). To better understand the
clinical indications for hospitalizations in these PAD
cohorts, we classiﬁed the associated ICD-9-CM pri-
mary diagnosis codes into mutually exclusive diag-
nosis categories on the basis of clinical similarity
using the Clinical Classiﬁcation Software (CCS). The
CCS was developed and is continually updated by
the Agency for Healthcare Research and Quality (25)
and consists of 2 related classiﬁcation systems, sin-
gle- and multi-level. We used single-level classiﬁ-
cations to descriptively compare hospital discharge
diagnoses between smokers and nonsmokers with
PAD.
STATISTICAL ANALYSIS. Continuous data are sum-
marized as mean  SD and categorical data asfrequency (percentage). Patient demographics, co-
morbid conditions, PAD risk factors, and hospitaliza-
tion episodes of care (percent hospitalized and
number of hospital episodes) were compared between
groups (smokers vs. nonsmokers) with Student t tests
or chi-square tests as appropriate. Observed mean
total direct medical costs and its individual compo-
nents were compared using Student t tests and non-
parametric bootstrapped conﬁdence intervals were
estimated (26).
To adjust for potential confounding by demo-
graphics and comorbid conditions, we conducted
multivariable modeling. Generalized linear modeling
assessed the impact of smoking status on total costs
(27), and used a logarithmic link function with a
gamma distribution on the basis of the modiﬁed Park
test (28). The method of recycled predictions was
used to assess differences in adjusted costs between
smokers and nonsmokers. The mean of the estimated
adjusted costs predicted for each individual in the
sample of assumed nonsmokers was subtracted from
the mean adjusted cost predicted for each individual
in the sample of assumed smokers; this statistic is
considered the adjusted cost difference attributable
to smoking. Bootstrapped 95% conﬁdence intervals
(CIs) of this mean difference were calculated and
differences assessed using Student t tests (29,30).
Separate models were run for the total PAD cohort
and pharmacy subgroup and for sample-speciﬁc total
costs and cost components (facility-based care costs
and professional service costs). To assess possible
effect modiﬁcation by concurrent cardiovascular
disease (CVD) on cost outcomes, analyses were
stratiﬁed on the basis of the presence or absence of
concurrent CVD, deﬁned as at least 1 episode of heart
failure, MI, or stroke. The 2 cohorts were also strati-
ﬁed by sex to assess possible differences in costs and
smoking-attributable cost differences in men and
women.
All statistical tests were two-tailed with an alpha
level of 0.05. Analyses were conducted in Stata
version 13.1 (StataCorp LP, College Station, Texas).
Alluvial diagrams were generated using the open-
source RAW data visualization tool (DensityDesign
Research Labs, Politecnico di Milano, Milan, Spain).
RESULTS
Very large PAD cohorts were identiﬁed for use in
this analysis. We identiﬁed 1,995 smokers (9.0%)
from a total of 22,203 Blue Cross enrollees in 2011
who met our inclusion criteria. Among the subgroup
of 9,027 PAD enrollees who had complete pharmacy
beneﬁts, we identiﬁed 1,158 (12.8%) smokers. In
TABLE 1 Population Characteristics (2011)*
Total PAD Cohort (N ¼ 22,203) Pharmacy Subgroup (n ¼ 9,027)
Smoker
(n ¼ 1,995)
Nonsmoker
(n ¼ 20,208) p Value
Smoker
(n ¼ 1,158)
Nonsmoker
(n ¼ 7,869) p Value
Age, yrs 69  11 78  10 <0.001 64  10 76  12 <0.001
Male 55.9 44.8 <0.001 56.1 44.2 <0.001
Minnesota/border
residence
84.4 78.8 <0.001 94.6 91.5 0.003
Plan type <0.001 <0.001
Commercial 37.3 23.1 58.4 58.0
Government
programs
26.6 25.1 19.5 19.6
Medicare
supplement
36.1 51.8 22.1 22.5
Hypertension 78.0 81.7 <0.001 73.6 78.0 0.007
Diabetes 11.1 16.4 <0.001 10.9 17.5 <0.001
Myocardial infarction 44.4 39.2 <0.001 40.0 35.5 0.003
Heart failure 18.0 23.0 <0.001 14.4 22.9 <0.001
Stroke 28.2 26.0 0.028 22.3 23.2 0.48
Renal failure 15.8 21.5 <0.001 13.6 20.5 <0.001
Cancer 14.4 11.2 <0.001 12.3 9.6 0.005
Values are mean  SD or %. *Comorbidities and risk factors deﬁned by International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation administrative diagnosis and procedure codes.
PAD ¼ peripheral artery disease.
TABLE 2 Annual Hospitalizations (2011)
Total PAD Cohort (N ¼ 22,203) Pharmacy Subgroup (n ¼ 9,027)
Smoker
(n ¼ 1,995)
Nonsmoker
(n ¼ 20,208) p Value
Smoker
(n ¼ 1,158)
Nonsmoker
(n ¼ 7,869) p Value
Percent hospitalized 49.0 36.4 <0.001 45.1 34.6 <0.001
In those with
$1 hospitalization
Number of hospital
encounters*
1.91 (1) 1.78 (1) 0.014 1.89 (1) 1.81 (1) 0.51
LOS, days† 8.81 (5) 8.72 (5) 0.29 9.05 (5) 8.67 (5) 0.24
All patients
Number of hospital
encounters‡
0.94 (0) 0.65 (0) <0.001 0.85 (0) 0.63 (0) <0.001
Values are % or mean (median). *Number of hospital encounters calculated only among those who had any
hospitalization. †Per hospital encounter for individuals who survived to discharge. ‡Calculated among all pa-
tients; those without a hospitalization were given a value of zero.
LOS ¼ length of stay; PAD ¼ peripheral artery disease.
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group, smokers were younger, male, and had higher
rates of MI and cancer than nonsmokers. Non-
smokers were more often hypertensive, diabetic,
and experienced heart failure or renal failure
(Table 1).
HOSPITALIZATIONS AND CLINICAL EVENTS. We
observed a total of 22,220 hospitalizations in the
total PAD cohort and 8,152 hospitalizations in
the pharmacy subgroup in 2011. Table 2 provides
details on these hospital events by cohort and
smoking status. The hospitalization rate was higher
for smokers compared with nonsmokers in both
samples with 49.0% of smokers hospitalized at least
once in 2011, compared to 36.4% of nonsmokers
(p < 0.001) in the larger PAD sample. Hospitaliza-
tion also was observed in 45.1% of smokers
compared to 34.6% of nonsmokers (p < 0.001) in
the pharmacy subgroup. Individuals with PAD
who smoked also experienced a signiﬁcantly higher
annual number of hospital episodes compared with
nonsmokers in the total PAD cohort, yet this dif-
ference was not found among the pharmacy sub-
group. The average hospital length of stay was
similar for smokers and nonsmokers who survived
to hospital discharge in both cohorts.
Classiﬁcation of the primary hospitalization dis-
charge diagnoses in both cohorts showed that
smokers were signiﬁcantly more likely than non-
smokers to be hospitalized for peripheral or visceral
atherosclerosis (p < 0.001), acute MI (p < 0.001), and
coronary heart disease (CHD) (p < 0.05) (Figure 1).
SMOKING-ATTRIBUTABLE HEALTH COSTS. Smoking
was associated with a very high differential cost
compared to nonsmokers in these 2 large PAD cohorts
per the 2011 data (Table 3). Observed costs were
$18,123 higher for smokers versus nonsmokers
(95% CI: $13,125 to $23,121) in the total PAD cohort and
$11,795 (95% CI: $6,244 to $17,346) higher for smokers
in the pharmacy subgroup. These differences per-
sisted after adjustment for age, sex, comorbid con-
ditions, insurance type, and Minnesota residence in
both the total PAD cohort (adjusted cost difference of
$17,673; 95% CI: $13,225 to $22,339) and the pharmacy
subgroup (adjusted cost difference of $11,780; 95% CI:
$7,105 to $16,538). Substantial smoking-attributable
costs were also observed in analyses of cost compo-
nents within both cohorts. In the total PAD cohort,
expenditures for facility-based care were estimated to
be $16,233 higher for smokers (p < 0.001) whereas
mean professional costs were estimated to be $1,502
higher for smokers compared with nonsmokers
(p < 0.001). The increased adjusted mean smokingattributable costs are likely due to more hospital
encounters in smokers.
In a further analysis of cost, we stratiﬁed our 2 PAD
cohorts by those with or without concurrent CVD.
Costs were much higher for those with concurrent
CVD, but the differences between smokers and non-
smokers were only slightly higher in the group with
concurrent CVD (Online Table 5a and b). With respect
to sex, stratiﬁed analyses showed that men not only
incurred greater costs than women in adjusted
models, but the differential cost between smokers
and nonsmokers was higher in men than in women
(data not shown).
FIGURE 1 Reasons for Hospitalization in Pharmacy Subgroup
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These alluvial plots display the broadest CCS-deﬁned primary discharge diagnosis during hospitalization (on the left) in smokers (A) and nonsmokers (B) in the pharmacy sub-
group,with 2 sequentiallymore speciﬁc CCS-deﬁned discharge diagnoses in themid-ﬁgure and to the right. The height of theblack bars (nodes) indicates the relative proportion
attributable to that condition, with discharge diagnoses ranked in descending order. COPD ¼ chronic obstructive pulmonary disease; CCS¼ clinical classiﬁcation software.
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These data show that smoking is associated with
an extremely high rate of hospitalizations and car-
diovascular ischemic events and procedures in thishigh-risk population (Central Illustration). Although it
has long been known that tobacco exposure exacer-
bates PAD-related clinical events, these are the ﬁrst
data to describe the impact of smoking on event rates.
The contribution of tobacco use to these acute and
TABLE 3 Cost* and Cost Differences† Between Smokers and Nonsmokers (2011)
Total PAD Cohort
Smoker
(n ¼ 1,995)
Nonsmoker
(n ¼ 20,208)
Difference
(Observed)‡
Difference
(Adjusted)‡ p Value
Total costs $64,041
($59,223-$68,859)
$45,918
($44,602-47,234)
$18,123
($13,125-$23,121)
$17,673
($13,225-$22,339)
<0.001
Total professional costs $9,049
($8,452-$9,646)
$5,757
($5,629-$5,885)
$3,292
($2,686-$3,899)
$1,502
($1,000-$2,033)
<0.001
Total facility-based care costs $54,992
($50,413-$59,571)
$40,162
($38,903-$41,421)
$14,830
($9,965-$19,696)
$16,233
($11,818-$21,008)
<0.001
Pharmacy Subgroup
Smoker
(n ¼ 1,158)
Nonsmoker
(n ¼ 7,869)
Difference
(Observed)‡
Difference
(Adjusted)‡ p Value
Total costs $56,826
($51,618-$62,034)
$45,031
($42,904-$47,158)
$11,795
($6,244-$17,346)
$11,780
($7,105-$16,538)
<0.001
Total professional costs $10,196
($9,294-$11,098)
$6,647
($6,387-$6,907)
$3,549
($2,617-$4,483)
$1,812
($1,043-$2,601)
<0.001
Total facility-based care costs $44,093
($39,267-$48,919)
$36,189
($34,180-$38,198)
$7,904
($2,609-$13,199)
$9,880
($5,404-$14,708)
0.003
Values are cost (95% conﬁdence interval). *Total costs include costs for facility-based care (hospital- and skilled nursing facilitybilled services and procedures) as well as costs
for professional care (primarily physician-billed services). †Cost differences are adjusted for age, sex, hypertension, diabetes, heart failure, renal failure, insurance type, and
Minnesota residence. ‡Difference data are reported as cost differences between smokers and nonsmokers (95% conﬁdence interval, generated using bootstrap [percentile
method]).
Abbreviations as in Table 1.
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1571chronic CHD and limb ischemic events is biologically
direct, as tobacco use is known to accelerate atheros-
clerosis, increase blood thrombogenicity, and risk of
plaque rupture (8). Ongoing exposure to tobacco isCENTRAL ILLUSTRATION Impact of Tobacco on PAD Clin
Duval, S. et al. J Am Coll Cardiol. 2015; 66(14):1566–74.
Tobacco is the single most powerful modiﬁable cause of atherosclerotic
events and hospitalizations. This is associated with an immense increase
CHD ¼ coronary heart disease; COPD ¼ chronic obstructive pulmonary
MALE ¼ major adverse limb event(s); PAD ¼ peripheral artery disease.associated with a very high short-term (1 year) incre-
mental cost increase of $18,000 per year in in-
dividuals with atherosclerotic lower extremity PAD.
Remarkably, medical costs in PAD nonsmokers areical Events and Cost: The Price of Inaction
PAD, markedly increasing the risk of CVD (MACE and MALE) and non-CVD clinical
in annual health care costs. Smoking cessation is effective and costs very little.
disease; CVD ¼ cardiovascular disease; MACE ¼ major adverse cardiac event(s);
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1572lower than those in smokers, despite the fact that the
nonsmokers are older and have a high prevalence of
diabetes, renal failure, and cancer, all of which are
known to increase costs. These much higher hos-
pitalization and clinical event rates, as well as sig-
niﬁcantly greater costs might, if better known
to patients, health care professionals, and payers,
immediately inform care standards (i.e., greater use
of prescription of tobacco cessation interventions)
and increase the priority given to smoking cessation
services. Each tobacco cessation attempt is remark-
ably inexpensive (31).
Prior investigations of the impact of smoking in PAD
patients have usually described the effect of tobacco
use on outcomes in small case series or limited out-
comes registries. The current study provides a more
powerful contribution to the PAD knowledge base by
its evaluation of the impact of smoking in a very
large PAD population (not a hospital-based vascular
specialty cohort) in which other key variables that
might alter health outcomes could be reasonably
evaluated.
These data conﬁrm that tobacco use leads to very
high short-term worsening in adverse cardiac and
limb ischemic outcomes. Parallel ﬁndings have been
reported for patients with chronic obstructive pul-
monary disease (COPD) and the documented effect
of smoking cessation intervention for COPD patients
is instructive. Ongoing tobacco use negatively im-
pacts lung function and increases hospitalization
rates for individuals with COPD (32). Provision of
smoking cessation interventions is associated with
a profound beneﬁcial impact on subsequent hospi-
talization rates, which were shown to decline by as
much as 43% in a Danish cohort (33). Such data
have served as the basis for emplacing tobacco
cessation programs within current care systems. For
example, the Minnesota Department of Health pro-
vides state-based surveillance of COPD and actively
promotes tobacco cessation interventions to lower
the health impact and cost of COPD within the
population (34). Similar efforts could be used to
lower the impact of atherosclerotic PAD on clinical
events and costs.
To our knowledge, no such effort now exists
within any national PAD clinical population. The
methods that are effective in achieving smoking
cessation in hospitalized patients are well-deﬁned
and the efﬁcacy of these interventions has been
shown by a series of randomized controlled trials in
medically compromised patients (35). Similarly,
these methods have also proven to be effective
in individuals with PAD (16). Thus, the current
data indicate a major opportunity to improveindividual and population health, and to do so cost
effectively.
STUDY LIMITATIONS. Although the current data are
informative and deﬁne the very high impact of
smoking in a contemporary PAD population, this
study has relevant limitations. First, administrative
datasets are not able to fully characterize the study
population, and risk factor exposures, for example,
precise estimates of the severity of dyslipidemia,
hypertension, and diabetes control, as well as use
of risk reduction medications, are not precisely
known. Similarly, the clinical PAD syndrome present
in these individuals (e.g., claudication vs. critical
limb ischemia) cannot be deﬁned. Physiologic data,
such as pulmonary function and ankle-brachial index
values that might predict clinical events are also un-
known. The impact of smoking in asymptomatic
populations also cannot be deﬁned from this dataset.
Smoking status in this study (9% to 13%), as
deﬁned by claims data, must certainly be under-
stated, as this prevalence is lower than that observed
in other PAD clinical cohorts, where current smoking
prevalence was 17% to 28% (1,36,37). This is a com-
monly observed consequence of administrative
datasets, which are derived from clinician and coder
use of relevant ICD-9 codes. Readers can best inter-
pret such administrative smoking exposure data by
noting that the reported “smoking prevalence” in the
general cohort represents a sampling of “past and
current smoking.”
We also report improved smoking ascertainment
within the pharmacy cohort subgroup, presuming
that active use of smoking cessation pharmacological
medications would provide a more precise estimate of
current tobacco use. Although tobacco use appears
low, note that contemporary smoking prevalence
among Minnesota seniors is, indeed, very low and
was recently reported as 5.4% (38). Although smoking
prevalence in our study is low, it is higher than the
general Minnesota population and represents a sam-
ple of those with PAD who smoke. Any under ascer-
tainment of tobacco exposure would have assigned
smokers inappropriately to the nonsmoking popula-
tion, diminishing the measured intergroup event and
cost differences. Thus, the true differential event and
cost effects of smoking are almost certainly higher
and this study provides a minimal estimate of the
tobacco use effect.
Assuming this directionality, the cost impact of
variable smoking cessation detection via billing code
use cannot be known securely. For example, smoking
identiﬁcation in billing codes (the general cohort) and
in the pharmacy cohort could represent physician
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: Tobacco
use has substantial adverse clinical and economic impact upon
patients with atherosclerotic PAD. Health systems commonly
provide access to endovascular, surgical and pharmacological
interventions to treat PAD but evidence-based smoking
cessation interventions are inconsistently available.
TRANSLATIONAL OUTLOOK: Prospective trials are needed
to compare the individual and population health and associ-
ated economic impact of various tobacco cessation techniques
and services for individuals with PAD who smoke.
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1573identiﬁcation of the sickest PAD patients and, thus,
lead to higher health care costs.
Smoking in individuals with PAD also is associ-
ated with other key negative health effects (e.g.,
worsened claudication) that we cannot measure.
These impacts may affect the ability of patients to
remain employed or participate in community ac-
tivities. A more complete estimate of cost would
include these unmeasured impacts. Future studies
should be performed to deﬁne these impacts from
other large national insured populations. An
adequately sized prospective cohort study or ran-
domized clinical tobacco cessation trial, with a
predeﬁned clinical event and health economic study
outcome, would provide the most reliable estimate
of the health and cost impact of tobacco in the PAD
population.
CONCLUSIONS
Tobacco use in patients with PAD is associated with a
very large increase in hospitalized clinical events and,
when individuals with PAD smoke, a much higher
fraction of hospitalized events are due to adverse car-
diac and PAD ischemic events. The tobacco-related
detrimental health impact is associated with asubstantial 30% increase in annual health expenditures.
This smoking-attributable health and economic burden
strongly suggests that tobacco cessation programs
would be especially cost effective for this population.
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